ATE481420T1 - Il-21-derivate - Google Patents

Il-21-derivate

Info

Publication number
ATE481420T1
ATE481420T1 AT04762905T AT04762905T ATE481420T1 AT E481420 T1 ATE481420 T1 AT E481420T1 AT 04762905 T AT04762905 T AT 04762905T AT 04762905 T AT04762905 T AT 04762905T AT E481420 T1 ATE481420 T1 AT E481420T1
Authority
AT
Austria
Prior art keywords
terminus
polypeptide
seq
derivatives
lipophilic substituent
Prior art date
Application number
AT04762905T
Other languages
English (en)
Inventor
Bernd Peschke
Christine Bruun Schiydt
Helle Woeldike
Florencio Zaragoza Doerwald
Anne Worsaae
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE481420T1 publication Critical patent/ATE481420T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
AT04762905T 2003-10-10 2004-10-08 Il-21-derivate ATE481420T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200301496 2003-10-10
US51089203P 2003-10-14 2003-10-14
DKPA200301529 2003-10-17
US51342203P 2003-10-22 2003-10-22
DKPA200400707 2004-05-04
US56956604P 2004-05-10 2004-05-10
PCT/DK2004/000686 WO2005035565A1 (en) 2003-10-10 2004-10-08 Il-21 derivatives

Publications (1)

Publication Number Publication Date
ATE481420T1 true ATE481420T1 (de) 2010-10-15

Family

ID=42779898

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04762905T ATE481420T1 (de) 2003-10-10 2004-10-08 Il-21-derivate

Country Status (7)

Country Link
EP (2) EP2263684A1 (de)
JP (1) JP2007533298A (de)
CN (2) CN1867581B (de)
AT (1) ATE481420T1 (de)
CA (1) CA2542179A1 (de)
DE (1) DE602004029173D1 (de)
WO (1) WO2005035565A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2385879C2 (ru) * 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
EP1877439B1 (de) 2005-04-18 2011-02-09 Novo Nordisk A/S Il-21-varianten
US20090047239A1 (en) * 2005-06-06 2009-02-19 Novo Nordisk A/S Stabilised IL-21 Compositions
AU2006286486A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
US8921518B2 (en) 2005-12-23 2014-12-30 Novo Nordisk A/S Purification of proteins using preparative reverse phase chromatography (RPC)
AU2007271150A1 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
WO2008074863A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
WO2015000585A1 (en) * 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
CN105198999A (zh) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 一种融合蛋白、其制备方法及其应用
KR20210119451A (ko) * 2019-01-21 2021-10-05 사노피 진행성 단계의 고형 종양 암에 대한 치료용 rna
WO2024002170A1 (en) * 2022-06-29 2024-01-04 Beijing Neox Biotech Limited Il-21 polypeptides and methods of use
CN117645661A (zh) * 2022-09-02 2024-03-05 北京志道生物科技有限公司 一种聚乙二醇修饰的il-21衍生物及其应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
EP0325224B1 (de) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1990013540A1 (en) 1989-04-19 1990-11-15 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ES2085297T3 (es) 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5492821A (en) 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2101918A1 (en) 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
CA2137087A1 (en) * 1992-06-01 1993-12-09 U. Prasad Kari Biologically active peptides having n-terminal substitutions
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5711944A (en) 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5686110A (en) 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996040248A1 (en) * 1995-06-07 1996-12-19 Eukarion, Inc. Transvacular and intracellular delivery of lipidized proteins
WO1996040791A1 (en) 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
PT964702E (pt) 1996-08-02 2006-12-29 Ortho Mcneil Pharm Inc Polipéptidos tendo um único polímero solúvel em água ligado ao n-terminal por covalência
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
CA2288994C (en) 1997-04-30 2011-07-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
ATE469166T1 (de) 1997-06-06 2010-06-15 Kyowa Hakko Kirin Co Ltd Chemisch modifizierte polypeptide
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
AU760381B2 (en) 1998-04-28 2003-05-15 Laboratoires Serono Sa PEG-LHRH analog conjugates
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
CN1827639A (zh) * 1999-03-09 2006-09-06 津莫吉尼蒂克斯公司 新的细胞因子zalpha11配体
ATE468862T1 (de) * 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
EP1432431B1 (de) * 2001-10-04 2017-05-10 Genetics Institute LLC Verfahren und zusammensetzungen zur modulierung der wirkung des interleukin-21
ES2334338T3 (es) 2001-11-05 2010-03-09 Zymogenetics, Inc. Antagonistas de il-21.
WO2003087320A2 (en) 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonists of il-21 and modulation of il-21-mediated t cell responses
EP1531850B1 (de) * 2002-06-07 2012-02-22 ZymoGenetics, Inc. Verwendung von IL-21 und monoklonalem Antikörper zur Behandlung von fester Tumore
AU2003251900B2 (en) 2002-07-15 2008-12-18 President And Fellows Of Harvard College Methods and compositions for modulating T helper (Th) cell development and function
MXPA05006117A (es) 2002-12-13 2005-09-30 Zymogenetics Inc Produccion de il-21 en hospederos procarioticos.
JP2007501811A (ja) * 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 治療的な関心対象のタンパク質に対する遅延分子の選択的な化学物質接合のためのガラクトースオキシダーゼの使用。

Also Published As

Publication number Publication date
EP2263684A1 (de) 2010-12-22
EP1673387B1 (de) 2010-09-15
CN1867581A (zh) 2006-11-22
CA2542179A1 (en) 2005-04-21
CN1867581B (zh) 2012-02-01
JP2007533298A (ja) 2007-11-22
EP1673387A1 (de) 2006-06-28
WO2005035565A1 (en) 2005-04-21
CN102516386A (zh) 2012-06-27
DE602004029173D1 (de) 2010-10-28

Similar Documents

Publication Publication Date Title
ATE481420T1 (de) Il-21-derivate
DK1941867T3 (da) Polypeptid med modificeret Kunitz domæne
BR9506733A (pt) Proteina de fusão de hematopoiese il-3 multivarian
ATE442378T1 (de) Substituierte wt1-peptide
IN2014CN02050A (de)
MX9200709A (es) Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas.
ATE495247T1 (de) Chromoprotein und fluoroproteine
ATE482272T1 (de) Zytokinproteinfamilie
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
BR0309491A (pt) Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes
DE60126602D1 (de) Neue collectine
ATE362769T1 (de) Lineare kationische peptide mit fungizider wirksamkeit
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
TW200505945A (en) Oligopeptides
DK2076532T3 (da) Cytokinderivater
JP2004505616A5 (de)
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
CA2530731A1 (en) Peptide having apoptosis-inhibiting activity
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
ECSP003457A (es) Derivados de proteina c
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
WO2003087352A3 (en) Enolase polypeptides and structures
WO2005047320A3 (en) Equine p-selection glycoprotein ligand-1 and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1673387

Country of ref document: EP